Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers

31Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

N6-methyladenosine RNA modification plays a significant role in the progression of multiple tumorigenesis. Our study identified the imperative role of m6A regulators in the tumor immune microenvironment, survival, stemness score, and anticancer drug sensitivity of pan-cancer. The Wilcox test was to identify the differential expression between 17 m6A regulators across 33 TCGA cancer types and their normal tissues from UCSC Xena GDC pan-cancer. Survival analysis of m6A-related regulators in 33 TCGA cancer types was identified using the “survival” and “survminer” package. The Spearman correlation test and Pearson correlation test were used to identify the correlation relationship between m6A regulators expression and tumor microenvironment, tumor stem cell score, and drug sensitivity of anticancer drugs. ConsensusPathDB was used for exploring m6A regulators functional enrichment. The 17 (METTL3, WTAP, METTL14, RBM15, RBM15B, VIRMA, HNRNPC, HNRNPA2B1, YTHDC1, ZC3H13, YTHDF1, YTHDC2, YTHDF2, IGF2BP3, IGF2BP1, FTO, and ALKBH5) m6A regulators were differentially expressed in 18 TCGA cancer types and adjacent normal tissues. Correlation analysis indicated that the relationship between the expression of 17 m6A regulators and tumor microenvironment indicated that the higher expression of m6A regulators, the higher the degree of tumor stem cells. The anticancer drug sensitivity analysis indicated that ZC3H13 expression had a positive relationship with anticancer drugs such as selumetinib, dabrafenib, cobimetinib, trametinib, and hypothemycin (p < 0.001). YTHDF2 expression was significantly negatively correlated with the anticancer drug dasatinib (p < 0.001). The pan-cancer immune subtype analysis showed that the 17 m6A regulators were significantly different in immune subtype C1 (wound healing), C3 (inflammatory), C2 (IFN-gamma dominant), C5 (immunological quiet), C4 (lymphocyte depleted), and C6 (TGF-beta dominant) (p < 0.001). Our study provides a comprehensive insight for revealing the significant role of m6A regulators in the tumor immune microenvironment, stemness score, and anticancer drug sensitivity of human cancers.

References Powered by Scopus

Cancer Statistics, 2017

14481Citations
N/AReaders
Get full text

Dynamic RNA Modifications in Gene Expression Regulation

2372Citations
N/AReaders
Get full text

The m<sup>6</sup>A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells

1175Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The roles and mechanism of m<sup>6</sup>A RNA methylation regulators in cancer immunity

92Citations
N/AReaders
Get full text

MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma

36Citations
N/AReaders
Get full text

ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer

32Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Li, R., Yin, Y. H., Ji, X. L., Liu, X., Li, J. P., & Qu, Y. Q. (2021). Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers. Frontiers in Molecular Biosciences, 8. https://doi.org/10.3389/fmolb.2021.644620

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

100%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 1

25%

Medicine and Dentistry 1

25%

Biochemistry, Genetics and Molecular Bi... 1

25%

Pharmacology, Toxicology and Pharmaceut... 1

25%

Save time finding and organizing research with Mendeley

Sign up for free